Neurocrine Biosciences Presents New 2-Yr Data From Phase 3 CAHtalyst Pediatric Study Showing Durable Androgen Control, Sustained Decreases In GC Doses And Clinical Improvements In Pediatric Patients With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

NBIX

0.00
  • At two years, 60% of patients who were overweight or obese at baseline experienced clinically meaningful improvements in body mass index, and 61% of those with insulin resistance at baseline were no longer insulin resistant
  • Improved outcomes associated with excess androgens, including acne and androstenedione-to-testosterone ratio were also observed
  • CRENESSITY delivered sustained reductions in adrenocorticotropic hormone and 17-hydroxyprogesterone, while enabling lower, more physiologic glucocorticoid dosing

SAN DIEGO, May 1, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the presentation of new two-year data from the Phase 3 CAHtalyst® Pediatric study demonstrating durable androgen control, sustained decreases in glucocorticoid (GC) doses and meaningful improvements in clinical outcomes associated with excess androgens and long-term GC exposure in children and adolescents with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont).

Consistent with these findings, patients with classic congenital adrenal hyperplasia (CAH) continued to experience substantial reductions in adrenocorticotropic hormone (ACTH) and 17-hydroxyprogesterone (17-OHP) while achieving lower, more physiologic GC doses. These data build upon previously reported one-year clinical outcomes results and were presented at the Pediatric Endocrine Society 2026 Annual Meeting in San Francisco.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.